Unofficial Copy J2

By: Senator Hollinger

Introduced and read first time: January 29, 2003 Assigned to: Education, Health, and Environmental Affairs

Committee Report: Favorable with amendments Senate action: Adopted Read second time: March 20, 2003

CHAPTER_____

1 AN ACT concerning

2 3

Board of Physician Quality Assurance - Office-Based, Medication-Assisted Opioid Addiction Therapy

4 FOR the purpose of requiring the Board of Physician Quality Assurance to establish

5 or designate a training and certification process program for certain physicians

6 on or before a certain date; requiring the Board to consult certain model

7 guidelines; requiring the Board to adopt certain regulations; requiring the

8 Board to educate physicians about certain provisions of federal law; requiring

9 the Board to inform physicians about the availability of a certain training and

10 certification process; requiring the Board to encourage certain physicians to

11 participate in certain therapies; requiring the Board to inform physicians about

12 the availability of certain training and experience; requiring the Board to offer

13 certain training opportunities to physicians; requiring the Board, in cooperation

14 with the Alcohol and Drug Abuse Administration, to develop a certain outreach

15 strategy; and generally relating to the State Board of Physician Quality

16 Assurance.

17

Preamble

WHEREAS, It is estimated that more than 60,000 Marylanders are addicted toopioid drugs such as heroin, morphine, and codeine; and

20 WHEREAS, Medication assisted treatment programs, including methadone

21 maintenance programs, are an effective means of reducing opioid use and assisting

22 addicts to become more productive citizens; and

SENATE BILL 224

1 WHEREAS, There are only 30 medication assisted treatment programs

2 currently operating in Maryland with approximately 9,000 slots funded by the Alcohol3 and Drug Abuse Administration; and

WHEREAS, In October of 2002, the federal Food and Drug Administration
approved two new prescription drugs, buprenorphine hydrochloride and
buprenorphine hydrochloride-naloxone hydrochloride, for the office-based treatment
of opiate dependence; and

8 WHEREAS, The federal Drug Addiction Treatment Act of 2000 authorizes 9 qualifying physicians to practice office-based, medication-assisted opioid addiction 10 therapy under a waiver from the federal Substance Abuse and Mental Health 11 Services Administration (SAMHSA); and

12 WHEREAS, One of the criteria by which physicians may qualify for waivers to 13 practice office-based, medication-assisted opioid addiction therapy is State medical 14 licensing board-approved experience or training in the treatment and management of 15 opiate-dependent patients; and

WHEREAS, Office-based treatment for opioid addiction will provide additional,
less stigmatized treatment options, promote higher turnover in the limited number of
medication-assisted treatment program slots, and enhance the cost-effectiveness of
medication-assisted treatment; and

20 WHEREAS, To date, only 22 Maryland physicians have obtained waivers to 21 provide office-based, medication-assisted opioid addiction therapy; and

WHEREAS, The State of Maryland should encourage physicians, particularly
primary care and family practice physicians, to pursue office-based,
medication-assisted opioid addiction therapy in order to expand access to substance
abuse treatment and make a positive public health impact; now, therefore,

26 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF 27 MARYLAND, That:

28 (a) On or before November 1, 2003, the State Board of Physician Quality

29 Assurance shall establish or designate a process program to train and certify

30 Maryland physicians who wish to apply for a waiver from SAMHSA to practice

31 office-based, medication-assisted opioid addiction therapy.

32 (b) In developing the establishing or designating a training and certification
 33 process program required under subsection (a) of this section, the Board shall:

(1) consult the Model Policy Guidelines for Opioid Addiction Treatment
 in the Medical Office adopted by the Federation of State Medical Boards of the United
 States, Inc.; and

37 (2) adopt regulations regarding the specific experience or training
 38 qualifications required to:

2

SENATE BILL 224

1(i)demonstrate the ability of the physician to treat and manage2opiate-dependent patients in an office-based setting; and
 3 (ii) qualify a physician for certification by the Board to apply for a 4 waiver from SAMHSA to practice office-based, medication-assisted opioid addiction 5 therapy.
6 (c) In implementing the process addition to establishing or designating a 7 program as required under subsection (a) of this section, the Board shall, through its 8 website, newsletter, and other correspondence with licensed physicians:
9 (1) educate licensed physicians about provisions of the federal Drug 10 Addiction Treatment Act of 2000 that authorize qualifying physicians to practice 11 office-based, medication-assisted opioid addiction therapy under a waiver from 12 SAMHSA;
 (2) inform licensed physicians about the availability of Board training and certification to qualify for a waiver to practice office based, medication assisted opioid addiction therapy;
16 (3) encourage family practitioners and primary care providers to 17 consider participating in office-based, medication-assisted opioid addiction therapy; 18 and
 19 (4) (3) provide training opportunities for inform licensed physicians 20 about the availability of training and experience to qualify for a waiver to practice 21 office-based, medication-assisted opioid addiction therapy that:
22(i)address addressesthe treatment and management of23opiate-dependent patients in an office-based setting; and
 24 (ii) satisfy satisfies the training requirements that the Board 25 establishes in the regulations adopted under subsection (b)(2) of this section.
 26 (d) To the extent feasible, the Board shall, in cooperation with the Alcohol and 27 Drug Abuse Administration, develop an outreach strategy to educate opioid addicts 28 about the availability of office-based, medication-assisted opioid addiction therapy.

SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effectOctober 1, 2003.

3

SENATE BILL 224